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Abstract
Hepatocellular carcinoma (HCC) is the most frequent primary malignant tumor of the 
liver, being the sixth most common cancer in the world and the third cause of cancer 
mortality. Most of the patients with HCC have an established background of cirrho-
sis and chronic liver disease. Magnetic resonance imaging (MRI) is the best technique 
for evaluation of the liver nodules in patients with cirrhosis, especially when a HCC is 
suspected. HCC staging is mandatory to select the appropriate primary and adjuvant 
therapy and to evaluate the prognosis. Hepatic resection is the treatment of choice in 
non-cirrhotic patients who have been diagnosed with HCC. In this chapter we underline 
the main diagnostic methods used for HCC staging, together with the treatment possi-
bilities, highlighting the importance of surgical management, conventional or minimally 
invasive.
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1. Introduction: generalities
Hepatocellular carcinoma (HCC) is the most frequent primary malignant tumor of the liver, 
which is arising from hepatocytes, the liver’s parenchymal cells. Most of the patients with 
HCC have an established background of cirrhosis and chronic liver disease due to hepatitis 
B virus or hepatitis C virus. HCC is the sixth most common cancer in the world and the third 
cause of cancer mortality [1].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Diagnosis
Clinical features of HCC may include pain in the upper right quadrant and weight loss. Most 
of the patients diagnosed with HCC are patients known with liver cirrhosis. Despite this fact, 
there is a rare complication such as rupture of a liver tumor with intra-abdominal bleeding, 
which will need immediate surgical care [2]. These patients will present with acute abdomi-
nal pain, peritoneal irritation and hypotension. Other patients present with nonspecific signs 
such as fever, jaundice, ascites, anorexia or encephalopathy [3].
Clinical examination can reveal an abdominal mass in the upper right quadrant or hepatomeg-
aly. Obstructive jaundice can indicate tumor extension into the extrahepatic biliary structures [4].
HCC can metastasize to any organ, the most frequent being metastasis to bone, lung or other 
abdominal viscera; so, patients can present with various clinical signs and symptoms related 
to the affected organs. Watery diarrhea is more common in patients with cirrhosis and HCC 
because of the increased production of intestinal secretory substances such as gastrin and 
vasoactive intestinal peptide (VIP) [5, 6].
Alpha-1 fetoprotein is the most commonly used marker for HCC. Patients with AFP > 400 ng/
ml tend to have a greater size, bilobar involvement, portal vein thrombosis and decreased 
survival [7]. If the tumor producing AFP is left untreated, the AFP value will increase over 
the time, so this marker can be used for detecting tumor progression. APF may be increased 
in a variety of other malignancies and in patients with chronic liver disease without HCC, 
particularly in hepatitis C [8]. The sensitivity, specificity and positive predictive value of AFP 
range from 39 to 64%, 76 to 91% and 9 to 32% [8]. Patients with values of AFP greater than 
1000 ng/ml have a higher incidence of vascular invasion (61%) compared with patients with 
values of AFP <1000 ng/ml [9].
Other clinical biomarkers used for the diagnosis of HCC are: microRNAs [10], des-gamma-
carboxyprothrombin (DCP) [11], glypican-3 (GPC3) [12], proteomic profiling [13], and alpha-
l-fucosidase [14].
Imaging has an important role in the diagnosis of HCC. Even if over the past decades the imag-
ing technology has improved and the hepatic lesions are better characterized, detection of the 
small tumors continues to be difficult especially in patients with liver cirrhosis whose paren-
chymal architecture is abnormal. The most common imaging techniques used for evaluation of 
the liver parenchyma are as follows: ultrasound scanning (US), CT scan, MRI, and angiography.
Ultrasound scanning is the most used technique, and it is performed as a routine test for screen-
ing focal hepatic lesions. Ultrasound imaging has now been replaced in diagnosis by CT scan 
and MRI. Contrast-enhanced ultrasound (CEUS) uses contrast agents such as intra-arterial 
dioxide carbon and helium. Also, application of color Doppler sonography can be useful in 
the assessment of intrahepatic vascular flow and the Doppler of the portal vein can differenti-
ate bland thrombus from tumor invasion.
Contrast-enhanced ultrasonography (CEUS) can offer information about the nature of the liver 
tumor which cannot be obtained with conventional ultrasonography. CEUS is safe, and it is 
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usually performed after detection of a focal lesion on standard US. The characterization of the 
hepatic lesion depends on all phases of contrast enhancement.
Most of the HCC are characterized by arterial phase enhancement and wash-out of the con-
trast during the late phase. According to some studies, more the differentiated a lesion is, the 
more gradually it is to washout [15, 16].
CEUS is an alternative for CT and MRI especially when there are contraindications for these 
investigations and it offers equivalent accuracy to CT and MRI if there is an experienced and 
skilled operator [17, 18].
CT scan is an important investigation for the characterization of the HCC. It includes 4 phases: 
pre-contrast, hepatic arterial phase, portal venous and delayed phases.
HCC must be differentiated from regeneration nodules, hemangioma, focal fat, dysplastic 
nodules and peliosis [19].
Factors such as injection of the contrast, tumor size and vascularity can affect the diagnostic 
accuracy of the HCC. In small tumors (less than 2 cm), the efficacy of CT is diminished due to 
the hypo-vascularization of small-sized tumors. The sensitivity of four phase CT in detecting 
HCC was up to 100% for tumors larger than 2 cm, 93% for tumors size between 1 and 2 cm 
and 60% for tumors less than 1 cm [20–22].
Multidetector helical CT (MDCT) is a new technique. which allows collection of early (18–28 s 
after administration of the contrast agent) and late or early parenchymal (35–45 s) arterial 
phase images. This new technique has improved the sensitivity and positive predictive val-
ues [23, 24]. Vascular tumors appear hypodense compared with liver parenchyma during the 
equilibrium phase (3–5 min after the administration of the contrast agent) and this technique 
is compared with MRI for early detection of small HCC (<1 cm) [24, 25].
Magnetic resonance imaging (MRI) is the best technique for evaluation of the liver nodules in 
patients with cirrhosis. HCC aspect varies on MRI because of the following factors: hemor-
rhage, degree of fibrosis and necrosis and histologic pattern. MRI is more accurate than CT 
or ultrasonography in detecting and characterization of HCC even for patients with liver cir-
rhosis. HCC appears hyper-intense on T2-weighted images while in T1-weighted images it 
may appear hypointense, isointense or hyperintense.
The sensitivity of MRI depends on tumor size, and it is about 95% in tumors larger than 2 cm 
and reduced to 30% for tumors, which are less than 2 cm in size [26].
Even if the MRI is the best investigation to characterize a liver nodule and to put the diag-
nosis of HCC, often the nodules might not be distinguished so a histological examination or 
advance imaging modalities will be necessary.
Angiography can be used to define hepatic anatomy before surgical resection.
Liver biopsy is performed with fine needle aspiration biopsy (FNAB) under ultrasonography or 
CT guidance and is considered the best method for a sure diagnosis of HCC. The sensitivity 
and specificity are about 96 and 95%, respectively, superior to any other test [27]. Sometimes, 
because the HCC lesions cannot be accurately located by radiographic methods, it is necessary 
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to perform open surgical biopsy. The most important complications are the risk of tumor spread-
ing along the needle tract, estimated at up 3%, important bleeding or infectious complications [7] 
[28–30]. Contraindications for liver biopsy are platelet count <50,000 per mm3 or the international 
normalizing ratio (INR) > 2 [7].
3. Diagnostic guidelines
According to European Association for the Study of the Liver (EASL):
• HCC lesions of greater than 2 cm in diameter can be diagnosed non-invasively in patients 
with cirrhosis based on radiographic criteria;
• Nodules with arterial hypervascularization in two imaging modalities or in only single 
imaging modality associated with values of AFP > 400 ng/ml in the cirrhotic liver is con-
sidered HCC [31];
• Evaluation of the liver nodules should be performed by US, CT and MRI; liver biopsy is 
not mandatory [32];
• EASL recommend repeated US every 3 months for lesions which are smaller than 1 cm, 
until it grows [31];
• Nodules between 1 and 2 cm in size are more likely to be HCC and confirmation by liver 
biopsy is recommended [33].
According to American Association for the Study of Liver Disease (AASLD):
• AFP > 200 ng/ml should lead to diagnostic suspicion of HCC and requires more investigation;
• Nodules <1 cm should be repeatedly imaged for up to 2 years;
• Nodules between 1 and 2 cm should be investigated with two techniques: CEUS, CT scan, 
MRI. If there is a hypervascularity with washout in the portal venous phase the lesion can 
be diagnosed as HCC [34];
• Nodules larger than 2 cm can be diagnosed as HCC with a use of only one imaging modal-
ity (arterial hypervascularity with wash-out in the early or delayed venous phase) [35];
• Liver biopsy is recommended if the vascular pattern is not characteristic for HCC on imag-
ing modalities [34].
4. Stadialization
HCC staging is mandatory to select the appropriate primary and adjuvant therapy and to 
evaluate the prognosis. There are eight different staging systems available for the management 
of HCC but none of them are universally accepted. The currently available staging systems for 
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HCC include: pathologic tumor-node-metastasis (pTNM) [36], Okuda [37], Cancer of the Liver 
Italian Program (CLIP) [38] and Barcelona Clinic Liver Cancer (BCLC) [39].
BCLC staging system seems to be the best for selection of early-stage HCC that should benefit 
from orthotopic liver transplantation, hepatic resection or local ablation while the CLIP score 
may be more useful at stratifying patients who are not candidates for resection or transplantation.
5. Treatment
Nowadays, many of the patients with HCC are diagnosed at an early stage when there are no 
signs of an advanced cancer. In the past, most of the patients were diagnosed only when they 
became symptomatic and no treatment had a chance of being effective or to improve the survival 
rates. There are a number of treatments available which seems to improve the survival rates, but 
to achieve the best results a careful selection of the patients is needed. Liver transplantation is 
the best option treatment for the patients with solitary HCC in the setting of decompensated cir-
rhosis and for those with early multifocal disease (up to 3 lesions, none larger than 3 cm) [40, 41], 
while for the patients with solitary tumors in well-compensated cirrhosis the best treatment 
strategy is under debate [42]. Treatments which offer the best survival rate are surgical resec-
tion, liver transplantation, percutaneous ablation and transarterial chemoembolization [40, 43]. 
Systemic chemotherapy has been demonstrated that has no benefits on survival rates [44, 45], 
while agents like tamoxifen [43], anti-androgens [46] or octreotide [47] are completely ineffective.
Hepatic resection is the treatment of choice in non-cirrhotic patients who have been diagnosed with 
HCC (Figure 1a and b). Patients with cirrhosis have to be very well selected for surgical resection 
due to the high risk of postoperative liver failure which can lead to death after the surgery. Cirrhotic 
patients have a higher rate of decompensation if they are operated with right hepatectomy than if 
a left hepatectomy is performed; however, the 5-year survival rate after resection can exceed 50% 
[42, 48, 49]. Before the surgery there are some specific factors which need to be considered:
• Stage of the tumor;
• Size of the tumor;
• Presence/absence of a chronic liver disease and portal hypertension assessed clinically or 
by hepatic vein catheterization. If the upper endoscopy shows varices or diuretic treatment 
is necessary, the portal hypertension is severe and there is no need for catheterization of 
the hepatic veins;
• Quality and volume of the future functional liver remnant.
The most important causes of death after liver resections are postoperative hemorrhages, liver 
failure and sepsis, but all these complications have a lower incidence due to the improve-
ments of the surgical techniques (Pringles maneuver), the development of ultrasonic dissec-
tors and vascular staplers.
To perform a right hepatic resection, you have to mobilize completely the right lobe of the liver 
to have control on the right hepatic vein before the parenchymal transection. Sometimes the 
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size of the tumors does not permit to mobilize the right lobe of the liver and to expose the 
anterior surface of the inferior vena cava, so the surgeon has to perform an anterior approach. 
The anterior approach implies initial completion of parenchymal transection before mobi-
lizing the right lobe of the liver and after hilar dissection is performed to control the right 
hepatic artery and portal vein. Intraoperative ultrasound is useful to mark on the Glisson 
capsule the plane of parenchymal transection. Transection is performed from the anterior 
surface of the liver down to right side of the liver hilum and down to the anterior surface of 
the inferior vena cava; then the right hepatic vein is isolated, clamped, divided and sutured. 
Only after the specimen is removed from the inferior vena cava, the right hepatic lobe is 
mobilized from the abdominal cavity by dividing the triangular ligament and other posterior 
attachments [50, 51].
Even if the anterior approach can be potentially dangerous because of the massive bleed-
ing which can occur when deeper plane of the parenchyma is transected, it is an effective 
alternative when difficulty is encountered during liver mobilization using the conventional 
technique [52].
One of the most important factors which can lead to recurrence are microportal invasion 
and intrahepatic metastasis, these being associated with a poor prognosis. Anatomic resection 
implies the systematic removal of a hepatic segment or segments bearing the tumors (Figure 2). 
This technique has been shown to be effective in eradicating intrahepatic metastasis of HCC 
and it is associated with a prolonged survival. From the oncological perspective, anatomical 
resections which include satellite lesions are more efficient than limited resections without a 
surrounding margin [53].
Laparoscopic liver resection was initially used for non-anatomic liver resection for peripheral 
benign tumors (Figure 3), but nowadays, with the development of instrumentation and tech-
niques, it has become a safe and feasible option for both benign and malignant liver lesions 
[54]. Regarding the advantages of laparoscopic liver resection, there are some advantages 
comparing with conventional liver resection such as reduced postoperative pain, less blood 
loss, less operative morbidity and a shorter length of hospitalization, while the long-term 
outcomes are similar especially for cirrhotic patients [55, 56].
Figure 1. (a) Segment V resection. Intraoperative aspect after removal of the specimen (from the personal archive of the 
authors). (b) Right hepatectomy. Intraoperative aspect after removal of the specimen (from the personal archive of the 
authors).
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Most of the patients with HCC are not suitable for the surgery due to the extent of the disease 
and because there is a high risk of liver failure. However, the patients with HCC who undergo 
surgery have a high risk of recurrence. The 5-year recurrence rate is about 77–100% and the 
median survival after the recurrence is between 7 and 28 months [57].
Predictors factors for the poor outcomes in HCC are the same for all therapeutic methods and 
they are: more than three tumors, tumor larger than 5 cm, portal vein invasion, intrahepatic 
metastases, absence of a tumor capsule, advanced TNM stage (III or IV), hepatitis C viral 
infection, and Child-Pugh class C [58, 59].
Figure 2. Anatomical resection of the VI–VII segments. Delimitation of the transection line after clamping the VI–VII 
pedicle (from the personal archive of the authors).
Figure 3. Laparoscopic liver resection of a HCC nodule (sg V) (from the personal archive of the authors).
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Liver resection may be used before the liver transplantation in three situations:
• Resection is used as primary treatment and liver transplantation will be an option for pa-
tients who develop liver failure or recurrence of the tumor;
• Resection is used as an initial treatment for patients who may undergo for liver transplan-
tation according to detailed examination of the history pathological examination;
• Resection is used as pre-treatment for the patients which are already enlisted for liver 
transplantation.
Liver transplantation is the best treatment option for patients diagnosed with HCC and cirrho-
sis Child-Pugh B and C. The Milan criteria [60] are a generally accepted set of criteria used to 
assess suitability in patients for liver transplantation with cirrhosis and HCC. These criteria 
are:
• single tumor with diameter ≤ 5 cm, or up to 3 tumors each with diameter ≤ 3 cm;
• no extra-hepatic involvement;
• no major vessel involvement.
Living-donor liver transplantation is a liver transplantation option which has developed over 
the last years due to the limited availability of deceased-donor organs and can be offered for 
patients with HCC if the waiting time is long enough to allow tumor progression leading 
to exclusion from the waiting list [61]. This technique uses the right or left hemiliver from a 
healthy donor and should be performed by expert surgeons to ensure the lowest morbidity 
and best outcome. Complications may appear in 20–40% of the donors, while the mortality 
risk for the donor is still 0.3–0.5% [62].
One of the main problems after the liver transplantation for HCC is the risk for recurrence 
of the tumor which occurs in 8–20% of the patients. Usually, the recurrence appears in 
the first 2 years after liver transplantation and is associated with a median survival less 
1 year [63].
For better results of the liver transplantation, there are some treatment options which can be 
performed before liver transplantation, such as liver resections or alcohol injection, radiofre-
quency ablation (RFA), transarterial chemoembolization (TACE), and transarterial radioem-
bolization/selective internal radiotherapy (TARE/SIRT). The main purpose of this treatment 
strategy is to reduce the size and number of the tumors in patients who do not have the 
accepted criteria for liver transplantation [64]. Most of the above techniques have been used 
as locoregional therapy for HCC recurrence in patients with limited disease.
Ablative techniques are useful for patients, which are not suitable for resection or liver trans-
plantation. Ablation can be done percutaneous, in open surgery or by laparoscopic approach 
and its purpose is to destruct the tumor cells by modifying the local temperature. The efficacy 
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of the percutaneous ablation is evaluated after 1 month with a CT scan (absence of the contrast 
uptake within the tumor reflecting tumor necrosis, while the persistence of contrast uptake 
indicates treatment failure) [31]. Recurrence rate is higher after ablation and the recurrence 
will occur nearby of the treated nodule due to the presence of microscopic satellites. Ablation 
must be performed under ultrasound guidance (Figure 4). Ablation techniques use chemical 
substances (ethanol, acetic acid, boiling saline) or surgical devices which modify the tempera-
ture of the tissue (radiofrequency, microwave, laser and cryotherapy).
Ethanol injection is highly effective for small HCC and has a low rate of complications, while 
the necrosis rate is about 90–100% of the HCC smaller than 2 cm. If the tumor size is between 
2 and 3 cm, the necrosis rate is reduced to 70 and 50%, respectively, for the tumor size between 
3 and 5 cm [65, 66]. Patients with Child-Pugh A class and HCC with successful tumor necrosis 
can achieve a 50% survival at 5 years [67, 68].
Radiofrequency ablation (RFA) is an option of treatment which has better result than ethanol 
injection and requires fewer treatment sessions [69, 70]. This type of treatment requires an 
insertion of single or multiple cooled tip electrodes or single electrodes with j-hooked needles 
that deliver heat around a wide region inducing necrosis of the tumor. This treatment is more 
efficient than ethanol injection but has a higher cost and a higher rate of complications such as 
Figure 4. Intraoperative laparoscopic ultrasound of the liver showing a HCC nodule in segment V, next to the gallbladder 
(from the personal archive of the authors).
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peritoneal bleeding or pleural effusion [69–72]. RFA can be performed by percutaneous under 
ultrasound guidance, open surgical approach or laparoscopic approach (Figure 5a and b). 
Some of the HCC cannot undergo for RFA due to their localization.
Transarterial embolization and chemoembolization are types of treatment which have developed 
over the last years because HCC exhibits intense neo-angiogenic activity and should be con-
sidered for patients who are not suitable for surgical resection or percutaneous ablation [61]. 
In patients with early-stage HCC, the blood supply comes from the portal vein and only when 
the tumor is larger it has an arterial blood supply from hepatic artery. This treatment purpose 
is to obstruct the hepatic artery to induce ischemia to the tumor. Hepatic artery obstruction 
is performed during an angiographic procedure and is known as transarterial embolization 
(TAE). If the transarterial embolization (TAE) is associated with the injection of chemothera-
peutic agents in the hepatic artery, the procedure is known as transarterial chemoembolization 
(TACE). The procedure needs advanced catheterization of the hepatic artery and the specific 
lobar and segmental branches to be as selective as possible and to reduce the damages of the 
nontumoral liver parenchyma. Chemotherapic agents such as adriamycin or cisplatin must be 
injected prior to arterial obstruction [73]. Contraindication for TAE/TACE is the lack of portal 
blood flow due to portal vein thrombosis, portosystemic anastomoses or hepatofugal flow [61]. 
Also, patients which advanced staged disease (Child-Pugh B and C) should not be considered 
for this treatment due to the high risk of hepatic failure. Side effects of intraarterial injection 
of the chemotherapeutic agents are nausea, vomiting, alopecia and sometimes, renal failure. 
After the transarterial embolization, the so-called post-embolization syndrome can appear, 
which consists of fever, abdominal pain and ileus. Post-embolization syndrome is usually self-
limited in less than 48 hours, but sometimes patients can develop hepatic abscess or cholecys-
titis. Regarding the response to this treatment there are no significant differences between TAE 
and TACE, the reported rate of objective response ranging from 16 to 60%, with a significant 
improvement in survival [43, 73].
Treatment algorithm is described in the next figure based on the Barcelona Clinic Liver Cancer 
(BCLC) staging classification [74]:
Figure 5. (a) US-guided intraoperative RFA of a liver tumor (from the personal archive of the authors). (b) Laparoscopic 
RFA of a HCC nodule. Intraoperative aspect (from the personal archive of the authors).
Liver Research and Clinical Management146
6. Perspectives
There are several areas where active research is needed, starting from molecular pathogenesis, 
to detection, diagnosis and treatment. Despite recent progress in the management of HCC, 
treatment of patients with portal vein thrombosis remains still a challenging area. Current 
clinical guidelines recommend Sorafenib only. However, besides Sorafenib, various therapies 
including surgery, TACE, external radiation therapy, hepatic artery infusion chemotherapy 
(HAIC) and radio-embolization may be considered in selected patients; the usefulness of 
combined treatment needs to be verified. Newer therapeutic options such as immunothera-
peutic agent and oncolytic virus are under investigation [75].
7. Conclusions
Management of HCC continues to be improved due to development of newer therapies which 
are combined with liver resection and liver transplantation. These therapies become better 
tolerated and more precise even in patients with advanced liver disease. Better surveillance of 
cirrhotic patients allowed an early detection of HCC and permitted treatments to have a higher 
rate of cure. For the patients who present with HCC and moderate to severe liver insufficiency, 
liver transplant remains a critical method to eliminate the cancer and cure the underlying liver 
disease with a lower risk of recurrence than resection or ablation. The best results for liver 
resection are obtained in patients with small solitary tumors, but there is a high rate of disease 
peritoneal bleeding or pleural effusion [
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blood flow due to portal vein thrombosis, portosystemic anastomoses or hepatofugal flow [
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recurrence due to cell dissemination prior to treatment. Improved survival for patients treated 
with Sorafenib for advanced disease increases enthusiasm for additional therapies for HCC.
Nowadays, the improvement of the surveillance will allow detection of the early stage of HCC 
when the loco-regional treatment is effective and transplantation is reserved only for selected 
cases. Alfa-fetoprotein and ultrasound scan should be used every 6 months for surveillance 
in high-risk individuals.
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